1
|
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Fruh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Thierstein S, Biaggi C, Opitz I. P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
2
|
Rothschild S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Britschgi C, Peters S, Mark M, Ochsenbein A, Janthur WD, Waibel C, Mach N, Gonzalez M, Froesch P, Godar G, Rusterholz C, Pless M. 1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.110] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
|
3
|
Joerger M, Metaxas Y, Schmitt A, Koeberle D, Zaman K, Betticher D, Mach N, Renner C, Mark M, Petrausch U, Caspar C, Britschgi C, Taverna C, Zenger F, Mingrone W, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R. LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA). Ann Oncol 2020. [PMCID: PMC7506361 DOI: 10.1016/j.annonc.2020.08.2321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
4
|
Sood R, Mancinetti M, Betticher D, Cantin B, Ebneter A. Management of bleeding in palliative care patients in the general internal medicine ward: a systematic review. Ann Med Surg (Lond) 2020; 50:14-23. [PMID: 31908774 PMCID: PMC6940657 DOI: 10.1016/j.amsu.2019.12.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2019] [Revised: 11/21/2019] [Accepted: 12/10/2019] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Palliative care patients, those suffering from at least one chronic lifelong medical condition and hospice care patients, those with a life expectancy less than 6 months, are regularly hospitalised in general internal medicine wards. By means of a clinical case, this review aims to equip the internist with an approach to bleeding in this population. Firstly, practical advice on platelet transfusions will be provided. Secondly, the management of bleeding in site-specific situations will be addressed (from the ENT/pulmonary sphere, gastrointestinal - urogenital tract and cutaneous ulcers). Finally, an algorithm pertaining to the management of catastrophic bleeding is proposed. METHODS Electronic databases, including EMBASE, Pubmed, Google Scholar and the Cochrane Library were studied as primary resources, in association with local guidelines, to identify papers exploring platelet transfusions and alternative management of site-specific bleeding in palliative care patients. RESULTS Haemorrhagic complications are frequent in palliative care patients in the internal medicine ward. Current guidelines propose a therapeutic-only platelet transfusion policy. Nonetheless, prophylactic and/or therapeutic transfusion remains a physician-dependent decision. Site-specific therapeutic options are based on expert opinion and case reports. While invasive measures may be pertinent in certain situations, their application must be compatible with patient goals. Catastrophic bleeding requires caregivers' comforting presence; pharmacological management is secondary. CONCLUSION Literature is lacking regarding management of bleeding in the palliative care population hospitalised in an acute medical setting. Recommendations are of limited quality, the majority based on case reports or expert opinion. Further studies, exploring for example the impact on patient quality of life, are desirable to improve the management of this frequently encountered complication.
Collapse
Affiliation(s)
- R. Sood
- Internal Medicine Department, Fribourg Hospital, Chemin des Pensionnats 2-6, 1752, Villars-sur-Glâne, Switzerland
| | - M. Mancinetti
- Internal Medicine Department, Fribourg Hospital, Chemin des Pensionnats 2-6, 1752, Villars-sur-Glâne, Switzerland
- Medical Education Unit, University of Fribourg, Avenue de l'Europe 20, 1700, Fribourg, Switzerland
| | - D. Betticher
- Internal Medicine Department, Fribourg Hospital, Chemin des Pensionnats 2-6, 1752, Villars-sur-Glâne, Switzerland
| | - B. Cantin
- Internal Medicine Department, Fribourg Hospital, Chemin des Pensionnats 2-6, 1752, Villars-sur-Glâne, Switzerland
- Palliative Care Department, Fribourg Hospital, Avenue Jean-Paul II 12, 1752, Villars-sur-Glâne, Switzerland
| | - A. Ebneter
- Internal Medicine Department, Fribourg Hospital, Chemin des Pensionnats 2-6, 1752, Villars-sur-Glâne, Switzerland
| |
Collapse
|
5
|
Mathey MP, de Jolinière JB, Major A, Conrad B, Khomsi F, Betticher D, Devouassoux M, Feki A. Rare case of remission of a patient with small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) stage IV: Case report. Int J Surg Case Rep 2019; 66:398-403. [PMID: 31978720 PMCID: PMC6976912 DOI: 10.1016/j.ijscr.2019.11.053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Revised: 11/18/2019] [Accepted: 11/24/2019] [Indexed: 02/08/2023] Open
Abstract
INTRODUCTION Small cell carcinoma of the ovary (SCC) is a very rare (less than 1 % of ovarien neoplasia), highly undifferentiated, aggressive malignancy affecting young women and linked to a poor prognosis. Overall survive rate is very low (about 16 %). SCCOHT has recently been shown to be associated with SMARCA4 gene mutations and shows some genetic similarities to malignant rhabdoid tumors (MRT). PRESENTATION OF CASE After a reminder of the clinical, histological description of the SCCOHT and concensus about the medical management, we describe the rare case of a 22 years old patient with complete remission after diagnosis of un undifferentiated SCCOHT stage IV treated by conservative surgery and high-doses chemotherapy, 30 months after diagnosis. DISCUSSION Thus far, no standard therapy exists for SCCOHT. Treatment modalities are surgery, chemotherapy, radiotherapy and autologous stem cell transplant after high-dose chemotherapy. Research for new treatments includes target therapy. CONCLUSION Autologous stem cell transplant after high-dose adjuvant chemotherapy seems to lead to the best survival rates. Invasiveness of the treatment depends on the stage of the disease, age of the patient and her fertility-sparing desire. An international collaboration will be needed to standardise practices due of the small number of patients.
Collapse
Affiliation(s)
- M P Mathey
- Département de chirurgie gynécologique et oncologique, Pr Dr Med A. Feki MD, PhD, HFR, Hôpital Cantonal, 6 chemin des pensionnats, Fribourg 1708, Switzerland; Institut fur med, OnKologie, Inselspital, 3010 Berne, Switzerland.
| | - J Bouquet de Jolinière
- Département de chirurgie gynécologique et oncologique, Pr Dr Med A. Feki MD, PhD, HFR, Hôpital Cantonal, 6 chemin des pensionnats, Fribourg 1708, Switzerland; Institut fur med, OnKologie, Inselspital, 3010 Berne, Switzerland.
| | - A Major
- Département de chirurgie gynécologique et oncologique, Pr Dr Med A. Feki MD, PhD, HFR, Hôpital Cantonal, 6 chemin des pensionnats, Fribourg 1708, Switzerland; Institut fur med, OnKologie, Inselspital, 3010 Berne, Switzerland
| | - B Conrad
- Département de chirurgie gynécologique et oncologique, Pr Dr Med A. Feki MD, PhD, HFR, Hôpital Cantonal, 6 chemin des pensionnats, Fribourg 1708, Switzerland; Institut fur med, OnKologie, Inselspital, 3010 Berne, Switzerland
| | - F Khomsi
- Département de chirurgie gynécologique et oncologique, Pr Dr Med A. Feki MD, PhD, HFR, Hôpital Cantonal, 6 chemin des pensionnats, Fribourg 1708, Switzerland; Institut fur med, OnKologie, Inselspital, 3010 Berne, Switzerland
| | - D Betticher
- Département d'Oncologie médicale, Pr Dr Med D. Betticher MHA, HFR, hôpital Cantonal, 6 chemin des pensionnats, Fribourg 1708, Switzerland; Institut fur med, OnKologie, Inselspital, 3010 Berne, Switzerland
| | - M Devouassoux
- Institut de pathologie Multi-Sites des HCL, Groupements hospitaliers Sud et nord, Pr M. Devouassoux MD, PhD, Centre de biologie et pathologie sud, Bat 3D 69495 Pierre Bénite Cedex, France; Institut fur med, OnKologie, Inselspital, 3010 Berne, Switzerland
| | - A Feki
- Département de chirurgie gynécologique et oncologique, Pr Dr Med A. Feki MD, PhD, HFR, Hôpital Cantonal, 6 chemin des pensionnats, Fribourg 1708, Switzerland; Institut fur med, OnKologie, Inselspital, 3010 Berne, Switzerland
| |
Collapse
|
6
|
Gerber A, da Silva Lopes A, Szüts N, Ribordy-Baudat V, Ebneter A, Perrinjaquet C, Betticher D, Cote M, Duchosal M, Brennan C, Decosterd S, Peters S, Koelliker R, Ninane F, Jeitziner MM, Colomer-Lahiguera S, Dietrich PY, Simon M, Gaignard ME, Eicher M. Adverse events in oncology and haemato-oncology inpatients of Swiss hospitals: A descriptive study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Müller A, Templeton AJ, Hayoz S, Hawle H, Hasler-Strub U, Schwitter M, Pestalozzi BC, Pagani O, Bützberger P, Wehrhahn T, Rauch D, Inauen R, Betticher D, Zaman K, Bodmer A, Popescu RA, Rothschild S, Schardt J, Borner M, Fuhrer A, Schär C, Gillessen S, von Moos R. Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-18-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Monthly Denosumab (DN) has shown superiority over zoledronic acid (ZA) in delaying skeletal related events. Randomized trials have shown that ZA given every 12 weeks (q12w) is non-inferior to ZA given every 4 weeks (q4w). The primary endpoint of the REDUSE-trial is non-inferiority for SSE for DN q12w versus q4w. Here we present early data for hypocalcemia (HC), a secondary endpoint.
Methods
Patients with bone metastasis from breast cancer (BC) not pretreated with DN or Bisphosphonates were randomized 1:1 to receive DN q4w (Arm A) versus q12w (Arm B) after a 3-month induction phase with q4w therapy for both arms. All patients received vitamin D 400 U (VitD) and calcium (Ca) 500 mg daily. Measurement of albumin-corrected serum-Ca was mandatory before each DN injection (HC defined as <2.0 mmol/l like in CTCAE V4.0). This safety interim analysis was performed after 3.5 years of accrual. Patients who received at least 1 dose of DN were considered evaluable.
Results
351 BC-patients are currently included (177 in Arm A, 174 in Arm B). HC was the most common side effect with a rate of 20% in the first 16 weeks (during the induction phase with DN q4w for both Arms) and 19% afterwards (combined for Arms A and B). After week 16 HC-prevalence differed between the two arms: while HC was present in 25% in Arm A (q4w), the rate was only 12% in Arm B (q12w). Grade 3 HC (i.e. corrected Ca 1.5 - 1.74 mmol/l or hospitalisation indicated) was rare (0.3%), no grade 4 HC occurred. After 1 year of treatment, the rate of HC compared to the induction phase had decreased in Arm B but not in Arm A (A: 25%, B: 12%). Since HC improved in more patients in Arm B than in Arm A whereas it worsened in more patients in Arm A than in Arm B, a remarkable difference for HC resulted between the two arms.
Rates of hypocalcemia and change of severity after week 16* Arm A (N = 177)Arm B (N = 174)Rates of hypocalcemian (%)n (%)Patients with hypocalcemia at any time49 (28%)46 (26%)Patients with hypocalcemia after week 16*44 (25%)21 (12%) Change in hypocalcemia grade after week 16*for the 49 patients with hypocalcemiafor the 46 patients with hypocalcemiaWorsening25 (51%)8 (17%)Stable10 (20%)9 (20%)Improving14 (29%)29 (63%) *week 16: i.e. the time where the schedules of DN begin to differ between Arm A and Arm BArm A: DN q4w for weeks 1 - 12 and likewise thereafter / Arm B: DN q4w for weeks 1 - 12 and q12w thereafter
Conclusions
In our trial up to 20% of all BC patients treated with DN experienced HC in the q4w induction phase despite mandatory supplementation of VitD and Ca. This rate is considerably higher than the numbers reported in the registration trials of DN (where it was 5.5% for BC). After the induction phase, HC is markedly reduced in the q12w arm compared to q4w. This suggests that DN given q12w has a more favorable long-term safety profile in terms of HC compared to DN q4w.
Citation Format: Müller A, Templeton AJ, Hayoz S, Hawle H, Hasler-Strub U, Schwitter M, Pestalozzi BC, Pagani O, Bützberger P, Wehrhahn T, Rauch D, Inauen R, Betticher D, Zaman K, Bodmer A, Popescu RA, Rothschild S, Schardt J, Borner M, Fuhrer A, Schär C, Gillessen S, von Moos R, For the Swiss Group for Clinical Cancer Research (SAKK). Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-18-01.
Collapse
Affiliation(s)
- A Müller
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - AJ Templeton
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - S Hayoz
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - H Hawle
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - U Hasler-Strub
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - M Schwitter
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - BC Pestalozzi
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - O Pagani
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - P Bützberger
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - T Wehrhahn
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - D Rauch
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - R Inauen
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - D Betticher
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - K Zaman
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - A Bodmer
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - RA Popescu
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - S Rothschild
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - J Schardt
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - M Borner
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - A Fuhrer
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - C Schär
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - S Gillessen
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | - R von Moos
- Kantonsspital Winterthur, Winterthur, Switzerland; St. Claraspital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital St. Gallen, St. Gallen, Switzerland; Kantonsspital Graubünden, Chur, Switzerland; Universitätsspital Zürich, Zürich, Switzerland; Ente Ospedaliero Cantonale Ticino, Bellinzona, Switzerland; Kantonsspital Baden, Baden, Switzerland; Kantonsspital Aarau, Aarau, Switzerland; Spital STS, Thun, Switzerland; Spital Thurgau, Münsterlingen, Switzerland; HFR Freiburg – Kantonsspital, Freiburg, Switzerland; Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland; Hospitaux Universitaires de Geneve HUG, Geneve, Switzerland; Hirslanden Medical Center, Aarau, Switzerland; Universitätsspital Basel, Basel, Switzerland; Inselspital, Universitätsspital Bern, Bern, Switzerland; Engeried & Lindenhofspital, Bern, Switzerland
| | | |
Collapse
|
8
|
Curioni-Fontecedro A, Ris HB, Xyrafas A, Bouchaab H, Gelpke H, Mach N, Matzinger O, Stojcheva N, Frueh M, Cathomas R, Berardi Vilei S, Bubendorf L, Pless M, Betticher D, Peters S. Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Ehmann M, Wannesson L, Pless M, Früh M, Gautschi O, Curioni-Fontecedro A, Betticher D, Mark M, Ochsenbein A, Rothschild S. Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor: Retrospective analysis of the Swiss Afatinib Named Patient Program. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx091.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Strasser F, Blum D, von Moos R, Cathomas R, Ribi K, Aebi S, Betticher D, Hayoz S, Klingbiel D, Brauchli P, Haefner M, Mauri S, Kaasa S, Koeberle D. The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Ann Oncol 2015; 27:324-32. [PMID: 26646758 DOI: 10.1093/annonc/mdv576] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Accepted: 11/16/2015] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Patients with advanced, incurable cancer receiving anticancer treatment often experience multidimensional symptoms. We hypothesize that real-time monitoring of both symptoms and clinical syndromes will improve symptom management by oncologists and patient outcomes. PATIENTS AND METHODS In this prospective multicenter cluster-randomized phase-III trial, patients with incurable, symptomatic, solid tumors, who received new outpatient chemotherapy with palliative intention, were eligible. Immediately before the weekly oncologists' visit, patients completed the palm-based E-MOSAIC assessment (Edmonton-Symptom-Assessment-Scale, ≤3 additional symptoms, estimated nutritional intake, body weight change, Karnofsky Performance Status, medications for pain, fatigue, nutrition). A cumulative, longitudinal monitoring sheet (LoMoS) was printed immediately. Eligible experienced oncologists were defined as one cluster each and randomized to receive the immediate print-out LoMoS (intervention) or not (control). Primary analysis limited to patients having uninterrupted (>4/6 visits with same oncologist) patient-oncologist sequences was a mixed model for the difference in patients global quality of life (G-QoL; items 29/30 of EORTC-QlQ-c30) between baseline (BL) and week 6. Intention-to-treat (ITT) analysis included all eligible patients. RESULTS In 8 centers, 82 oncologists treated 264 patients (median 66 years; overall survival intervention 6.3, control 5.4 months) with various tumors. The between-arm difference in G-QoL of 102 uninterrupted patients (intervention: 55; control: 47) was 6.8 (P = 0.11) in favor of the intervention; in a sensitivity analysis (oncologists treating ≥2 patients; 50, 39), it was 9.0 (P = 0.07). ITT analysis revealed improvement in symptoms (difference last study visit-BL: intervention -5.4 versus control 2.1, P = 0.003) and favored the intervention for communication and coping. More patients with high symptom load received immediate symptom management (chart review, nurse-patient interview) by oncologists getting the LoMoS. CONCLUSION Monitoring of patient symptoms, clinical syndromes and their management clearly reduced patients' symptoms, but not QoL. Our results encourage the implementation of real-time monitoring in the routine workflow of oncologist with a computer solution.
Collapse
Affiliation(s)
- F Strasser
- Oncological Palliative Medicine, Clinic Oncology/Hematology, Department of Internal Medicine and Palliative Center, Cantonal Hospital St Gallen, St Gallen, Switzerland
| | - D Blum
- Oncological Palliative Medicine, Clinic Oncology/Hematology, Department of Internal Medicine and Palliative Center, Cantonal Hospital St Gallen, St Gallen, Switzerland European Palliative Research Centre, NTNU, and St Olavs University Hospital Trondheim, Trondheim, Norway
| | - R von Moos
- Department of Oncology, Cantonal Hospital Chur, Chur
| | - R Cathomas
- Department of Oncology, Cantonal Hospital Chur, Chur
| | | | - S Aebi
- Department of Oncology, University Hospital Bern, Bern
| | - D Betticher
- Department of Oncology, Cantonal Hospital Fribourg, Fribourg
| | - S Hayoz
- SAKK Coordinating Center, Bern
| | | | | | | | - S Mauri
- Department of Oncology, Cantonal Hospital Lugano, Lugano
| | - S Kaasa
- European Palliative Research Centre, NTNU, and St Olavs University Hospital Trondheim, Trondheim, Norway
| | - D Koeberle
- Clinic Oncology/Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
| | | |
Collapse
|
11
|
Kamber C, Zimmerli S, Suter-Riniker F, Mueller BU, Taleghani BM, Betticher D, Zander T, Pabst T. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplant 2015; 50:573-8. [PMID: 25599166 DOI: 10.1038/bmt.2014.290] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Revised: 10/08/2014] [Accepted: 10/10/2014] [Indexed: 11/09/2022]
Abstract
The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). We determined the incidence and the prognostic significance of HZ and its correlation with VZV serology in 191 consecutive myeloma patients undergoing high-dose melphalan chemotherapy with ASCT. We found that VZV reactivation occurred in 57 (30%) patients, in 8.5% during induction and in 21.5% after ASCT peaking at 8 months after ASCT. Disease burden due to HZ was assessed as high or rather high in 70% of the patients. By immune fluorescence and Serion Elisa VZV IgG assessment, 90.8% of all patients had specific anti-VZV antibodies at ASCT. Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation (P=0.009). Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ (P=0.007). Our data indicate that VZV reactivation after ASCT is a frequent event carrying a significant disease burden and it is associated with improved survival. Low levels of specific VZV antibodies at ASCT suggest increased vulnerability for VZV reactivation.
Collapse
Affiliation(s)
- C Kamber
- Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland
| | - S Zimmerli
- Department of Infectious Diseases, University Hospital and University of Bern, Bern, Switzerland
| | - F Suter-Riniker
- Department of Infectious Diseases, University Hospital and University of Bern, Bern, Switzerland
| | - B U Mueller
- Department of Clinical Research, University Hospital and University of Bern, Bern, Switzerland
| | - B M Taleghani
- Department of Hematology, University Hospital and University of Bern, Bern, Switzerland
| | - D Betticher
- Department of Oncology, Cantonal Hospital, Fribourg, Switzerland
| | - T Zander
- Department of Medical Oncology, Cantonal Hospital, Lucerne, Switzerland
| | - T Pabst
- Department of Medical Oncology, University Hospital and University of Bern, Bern, Switzerland
| |
Collapse
|
12
|
Bouquet de Jolinière J, Ben Ali N, Fadhlaoui A, Dubuisson JB, Guillou L, Sutter A, Betticher D, Hoogewoud HM, Feki A. Two case reports of a malignant germ cell tumor of ovary and a granulosa cell tumor: interest of tumoral immunochemistry in the identification and management. Front Oncol 2014; 4:97. [PMID: 24982844 PMCID: PMC4055855 DOI: 10.3389/fonc.2014.00097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2014] [Accepted: 04/18/2014] [Indexed: 12/22/2022] Open
Abstract
Objective: In this article, we present two case reports. The first case was a malignant germ cell tumor of the right ovary in a 23-year old woman and the second case was a bilateral undifferentiated granulosa cell tumor in a 71-year old woman. The aim of these reports is to illustrate the interest of the immunohistochemical analysis to define the correct diagnosis, to better classify these ovarian tumors and improve their management. Methods: In this study, we report two cases. The first case concerns a 23-year old woman (A) with a mixed germ cell tumor of the right ovary [dysgerminoma (75%), yolk sac tumor (20%), and a mature teratoma (5%)], and the second case concerns a 71-year old woman (B) with a bilateral non-differentiated and necrotic granulosa cell tumor of both ovaries. The staging system was used according to both the classifications: International Federation of Gynaecology and Obstetrics 1987 for ovarian cancer and TNM code 2009. Results: The immunostaining establishes the malignancy and the immunochemistry contributes to confirm effectively the right diagnosis (Tables 2 and 3). Conclusion: An immunohistochemical analysis is mandatory for the choice of chemotherapy to obtain a better response of the disease and improve the survival prognosis. The efficiency of the chemotherapy authorizes a conservative surgery including a unilateral salpingo-oophorectomy preserving fertility (A). Concerning the non-dysgerminoma tumor (B), and after a surgical staging and debulking, chemotherapy was recommended. The type of tumor and its histological feature conditioned the choice of treatment. The benefit of the immunohistological analysis in this case allowed the right adjuvant treatment.
Collapse
Affiliation(s)
| | - N Ben Ali
- Department of Obstetrics and Gynecology, Hôpital Fribourgeois , Fribourg , Switzerland
| | - A Fadhlaoui
- Department of Obstetrics and Gynecology, Hôpital Fribourgeois , Fribourg , Switzerland
| | - J B Dubuisson
- Department of Obstetrics and Gynecology, Hôpital Fribourgeois , Fribourg , Switzerland
| | - L Guillou
- Argot Laboratory Lausanne, Department of Pathology and Cytology , Lausanne , Switzerland
| | - A Sutter
- Argot Laboratory Lausanne, Department of Pathology and Cytology , Lausanne , Switzerland
| | - D Betticher
- Department of Oncology, Hôpital Fribourgeois , Fribourg , Switzerland
| | - H M Hoogewoud
- Department of Radiology, Hôpital Fribourgeois , Fribourg , Switzerland
| | - A Feki
- Department of Obstetrics and Gynecology, Hôpital Fribourgeois , Fribourg , Switzerland
| |
Collapse
|
13
|
Zimmermann A, Cantin B, Fournier F, Betticher D. [The transition of palliative care from the hospital to the ambulatory care of the general practitioner: the experience in the canton of Fribourg]. Rev Med Suisse 2014; 10:811-815. [PMID: 24791427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Thanks to medical progress, the life expectancy of a majority of severely ill patients has greatly improved. The fact that these patients will live longer with their disease encourages new solutions to respond to the challenges of care continuity, coordination, interprofessional and interinstitutional collaboration. Palliative care represents a chain management based on the involvement of every professional in acute care hospitals, palliative care units, nursing homes and private homes. The collaboration among the different players as well as their education are essential elements linked to the quality of care, to the quality of life for both patients and their relatives.
Collapse
|
14
|
Zimmermann S, Betticher D. [New anticancer drugs: much ado about nothing?]. Rev Med Suisse 2014; 10:788-793. [PMID: 24791424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Multiple new cancer drugs have been marketed during the last decade, and among those many molecularly targeted agents. Their impact on clinical outcomes population-wide remains hard to measure. Are we merely seeing the development of expensive and toxic drugs that benefit a minority of patients, or are battles actually won in the war on cancer? Both epidemiologic trends and clinical trial data show that a patient's outcome today is significantly better than 10 or 20 years ago, in terms of cure rates and survival time for advanced disease.
Collapse
|
15
|
Hayoz D, Betticher D. [The future is not what it was...and this may well be so!]. Rev Med Suisse 2014; 10:779-780. [PMID: 24791422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
16
|
Hemett OM, Martins F, Descombes E, Betticher D, Hayoz D. [Thrombotic microangiopathy: when time is the key factor!]. Rev Med Suisse 2014; 10:794-803. [PMID: 24791425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Thrombotic microangiopathy or "TMA" including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) became a public health problem following the European outbreak of E. coli (O104:H4) gastroenteritis in 2011. A rapid diagnosis and therapy in an intensive care unit provide better patient survival and lower cost for society. Supportive treatment has significantly improved the prognosis over the past decade and includes fresh frozen plasma for TTP, plasmapheresis for HUS, and recently a new therapeutic agent: anti-C5 antibodies. We will provide in this article, through the current literature and four cases encountered in our department, to establish an algorithm to manage patients with TMA.
Collapse
|
17
|
Joerger M, Baty F, Stahel R, Betticher D, von Moos R, Pless M, Gautschi O, Brauchli P, Zappa F, Brutsche M. 25PD CIRCULATING MICRO-RNA PROFILING IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON SMALL-CELL LUNG CANCER RECEIVING BEVACIZUMAB/ERLOTINIB FIRST-LINE TREATMENT FOLLOWED BY PLATINUM-BASED CHEMOTHERAPY AT DISEASE PROGRESSION (SAKK 19/05). Lung Cancer 2013. [DOI: 10.1016/s0169-5002(13)70246-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
18
|
Hayoz D, Betticher D. [Fribourg to zenith?]. Rev Med Suisse 2010; 6:2163-2164. [PMID: 21155289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
|
19
|
Taverna C, Bargetzi M, Betticher D, Gmür J, Gregor M, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Renner C. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss Med Wkly 2010; 140:w13054. [PMID: 20458652 DOI: 10.4414/smw.2010.13054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma.
Collapse
Affiliation(s)
- C Taverna
- Medizinische Klinik, Kantonsspital Münsterlingen, 8596 Münsterlingen, CH, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Kirson ED, Weinberg U, Betticher D, Von Moos R, Fischer N, Studt J, Buess M, Burger N, Palti Y, Pless M. A phase I study of tumor treating fields (TTFields) in combination with pemetrexed for pretreated advanced non-small cell lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e18500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18500 Background: TTFields (tumor treating fields) are low intensity, intermediate frequency, alternating electric fields which slow the growth of solid tumors in-vivo, and have shown promise in pilot clinical trials in patients with advanced solid tumors. TTFields are a regional treatment which acts both by interfering with microtubules polymerization and by physical disruption of the cell structure during cytokinesis. It has been shown previously that TTFields sensitize non-small cell lung cultures to Pemetrexed. In-Vivo, TTFields did not increase pemetrexed related toxicity. Methods: A prospective trial was performed in 14, pretreated, stage IIIb-IV, NSCLC patients. Patients with brain metastases were excluded, as were patients with abnormal marrow, kidney, liver or cardiac functions. Patients with history of clinically significant arrhythmias or those having pacemakers were excluded as well. Patients received Pemetrexed 500mg/m2 IV q3w together with daily TTFields (12 h/day) using a portable medical device (NovoTTF-100L). The device generated 2 direction (AP and Lat), 150 kHz TTFields. Patients were followed every three weeks and had a lung CT every 9 weeks. The primary endpoint was the safety and tolerability of the NovoTTF-100L device in combination with pemetrexed. Results: The 14 patients received an average of 4 courses of pemetrexed (Range 1–9) and a cumulative TTFields treatment time of 182 weeks. The device was well tolerated as indicated in the device log files which showed an average daily use of 11±1 hours. There were no device-related, nor pemetrexed-related SAEs. In addition, no unexpected abnormalities were evident in the lab tests or EKGs, done every 3 weeks for all patients. There were no reports of arrhythmias. The only device related AE seen in all patients was dermatitis under the electrodes. This improved with meticulous skin care, topical steroid use and in extreme cases oral steroids. One patient (7.6%) had a CR, 1 a PR (7.6%), 9 SD (69.2%) and 3 PD (23%). 77% of patients were progression free at 12 weeks and the 6 month survival was 89%. Conclusions: TTFields are well tolerated when given together with pemetrexed. The excellent safety profile and initial efficacy results reported here justify further clinical testing. [Table: see text]
Collapse
Affiliation(s)
- E. D. Kirson
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - U. Weinberg
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - D. Betticher
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - R. Von Moos
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - N. Fischer
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - J. Studt
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - M. Buess
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - N. Burger
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - Y. Palti
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| | - M. Pless
- NovoCure Ltd., Haifa, Israel; NovoCure, Haifa, Israel; Hôpital Fribourgeois - Site de Fribourg, Fribourg, Switzerland; Kantonsspital Graubunden, Chur, Switzerland; University Hospital Basel, Basel, Switzerland; Claraspital, Basel, Switzerland; Kantonsspital Winterthur, Winterthur, Switzerland
| |
Collapse
|
21
|
Pless M, Stupp R, Kann R, Zouhair A, Mayer M, Thierstein S, Stahel R, Betticher D, Balmer Majno S, Ris HB. Preoperative chemoradiotherapy in non-small cell lung cancer (NSCLC) patients with operable stage IIIB disease. A phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18021 Background and Methods: Outcome of patients (pts) with locally advanced NSCLC treated with radio- or chemoradiotherapy is poor. This two-stage phase II trial (planned sample size 46) aimed at evaluating feasibility and outcome of a tri-modality concept of neoadjuvant chemotherapy (CT), radiotherapy (RT) followed by definitive surgery in operable, stage IIIB NSCLC pts. Treatment consisted of 3 cycles of cisplatin (100 mg/m2) and docetaxel (85 mg/m2) followed by accelerated, concomitant boost RT (44 Gy/22 fx) and surgery. Primary endpoint is event-free survival at 1 year. Operable pts up to age 75 and a performance status of 0–1 with stage IIIB NSCLC (pleural effusion excluded) were eligible. Results: Forty-five eligible pts (46 accrued) with a median age was 60 years (range 28–70) were treated between September 2001 and May 2006. Tumor location was right-sided in 28 pts and left-sided in 17 pts. Histology was squamous cell 42%, large cell 11%, adeno-13% and undifferentiated carcinoma 33%. N3-disease was present in 29%, T4 stage in 78%. CT (45 pts) and RT (34 pts) were delivered as prescribed in >80% of cycles. The median time from enrollment to surgery was 3.7 months (2.8 - 5.2). The objective response rate after CT was 53% (95% c.i. 38–68%), after additional RT 67% (51–80%). Surgery (pneumonectomy in 17) was performed in 31 pts (69%), with an R0 resection in 24 pts. Median duration of hospitalization was 12 days (8–134). Two pts died in the perioperative phase due to ARDS and a cerebro-vascular event, respectively. Mature results of the primary endpoint and overall survival will be available at the ASCO meeting. Conclusions: Combined multimodality treatment strategy is feasible in a subgroup of patients, with acceptable toxicity. About two thirds of patients responded to the induction therapy, and were able to undergo subsequent surgery. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Pless
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - R. Stupp
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - R. Kann
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - A. Zouhair
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - M. Mayer
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - S. Thierstein
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - R. Stahel
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - D. Betticher
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - S. Balmer Majno
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| | - H. B. Ris
- Cantonal Hospital, Winterthur, Switzerland; University Hospital CHUV, Lausanne, Switzerland; University Hospital, Basel, Switzerland; SAKK Coordinating Center, Bern, Switzerland; University Hospital, Zurich, Switzerland; Cantonal Hospital, Fribourg, Switzerland; University Hospital HUG, Geneva, Switzerland
| |
Collapse
|
22
|
Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R, Ris HB, Jermann M, Mingrone W, Roth AD, Spiliopoulos A. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18:1196-202. [PMID: 17429100 DOI: 10.1093/annonc/mdm093] [Citation(s) in RCA: 218] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The aim of this multicenter trial was to prospectively evaluate neo-adjuvant chemotherapy followed by extrapleural pneumonectomy (EPP) and radiotherapy, including quality of life as outcome. PATIENTS AND METHODS Eligible patients had malignant pleural mesothelioma of all histological types, World Health Organization performance status of zero to two and clinical stage T1-T3, N0-2, M0 disease considered completely resectable. Neo-adjuvant chemotherapy consisted of three cycles of cisplatin and gemcitabine followed by EPP. Postoperative radiotherapy was considered for all patients. RESULTS In all, 58 of 61 patients completed three cycles of neo-adjuvant chemotherapy. Forty-five patients (74%) underwent EPP and in 37 patients (61%) the resection was complete. Postoperative radiotherapy was initiated in 36 patients. The median survival of all patients was 19.8 months [95% confidence interval (CI) 14.6-24.5]. For the 45 patients undergoing EPP, the median survival was 23 months (95% CI 16.6-32.9). Psychological distress showed minor variations over time with distress above the cut-off score indicating no morbidity with 82% (N = 36) at baseline and 76% (N = 26) at 3 months after surgery (P = 0.5). CONCLUSIONS The observed rate of operability is promising. A median survival of 23 months for patients undergoing EPP compares favourably with the survival reported from single center studies of upfront surgery. This approach was not associated with an increase in psychological distress.
Collapse
Affiliation(s)
- W Weder
- Department of Thoracic Surgery, University Hospital Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
D’Addario G, Strasser F, Ribi K, Rauch D, Stupp R, Pless M, Stahel RA, Rufibach K, Lerch S, Betticher D. Quality of life (QoL) in SAKK 19/03: A multicenter phase II study of first-line gefitinib followed by chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18559 Background: 63 patients (pts) were accrued in this first study testing first-line tyrosine-kinase inhibitor treatment with gefitinib followed by chemotherapy at disease progression (gemcitabine-cisplatin q3w x6, 41 pts) in stage IIIB/IV NSCLC (ASCO 2005 # 7128). We investigated the longitudinal QoL patterns on both subsequent treatment modalities. Methods: FACT-L including TOI (Trial Outcome Index) and LCS (Lung Cancer Subscale) scores were assessed during both treatment phases (gefitinib: baseline, weeks 3,6,12,18 and every 12 weeks thereafter; chemotherapy: baseline and at d1 of cycle 3 and 5). QoL changes from baseline were descriptively analysed. Improvement was defined as a 6 point (FACT-L, TOI) and 2 point (LCS) increase. Results: QoL-scores are shown in the table below. On gefitinib, at week 6 31/18/32% of pts had improvements of FACT-L, TOI and LCS, respectively and 29/15/41% at week 12 (% based on pts with available data). During chemotherapy the respective improvement rates were 60/60/70% of pts at week 6 and 43/29/43% at week 12. At week 12 of gefitinib, 4 of the pts analysed had partial remission (PR, independently confirmed), 31 pts dropped out (none due to toxicity) and QoL submission rate was 84% based on expected forms. Chemotherapy week 12: 5 PR in analysed pts, 18 drop outs (5 due to toxicity), 43% submission rate. Conclusions: QoL was maintained in pts continuing treatment with gefitinib and decreased at disease progression. QoL and tumor symptoms improved in a considerable part of pts during gefitinib therapy despite low remission rates. Declining submission rate during treatment introduces a potential, unquantifiable bias in QoL. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- G. D’Addario
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - F. Strasser
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - K. Ribi
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - D. Rauch
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - R. Stupp
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - M. Pless
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - R. A. Stahel
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - K. Rufibach
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - S. Lerch
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| | - D. Betticher
- Kantonsspital, St. Gallen, Switzerland; IBCSG/SAKK QoL Office Coordinating Center, Bern, Switzerland; Spital, Thun, Switzerland; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Universitaetsspital, Basel, Switzerland; Universitaetsspital, Zuerich, Switzerland; SAKK Coordinating Center, Bern, Switzerland; Kantonsspital, Fribourg, Switzerland
| |
Collapse
|
24
|
Gautschi O, Huegli B, Ziegler A, Bigosch C, Ratschiller D, Bowers N, Stahel R, Heighway J, Betticher D. P-484 CCND1/Cyclin D1 A870G gene polymorphism is associated with non-small cell lung cancer (NSCLC) risk, and affects prognosis and response to chemotherapy. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80977-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Weder W, Stahel R, Vogt P, Bernhard J, Ris H, Stupp R, Schmid R, Betticher D, Ballabeni P, Bodis S. P-436 Neoadjuvant chemotherapy followed by pleuropneumonectomy and radiotherapy for pleural mesothelioma: A multicenter phase II trial of the SAKK. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80929-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Gridelli C, Manegold C, Mali P, Reck M, Portalone L, Castelnau O, Stahel R, Betticher D, Pless M, Pons JT, Aubert D, Burillon JP, Parlier Y, De Marinis F. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 2004; 40:2424-31. [PMID: 15519515 DOI: 10.1016/j.ejca.2004.07.028] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2004] [Accepted: 07/15/2004] [Indexed: 10/26/2022]
Abstract
Vinorelbine intravenously (i.v.) demonstrated its efficacy and tolerability in advanced non-small cell lung cancer (NSCLC) patients, including elderly subjects. Since vinorelbine is now available as an oral formulation this phase II open study was designed to evaluate its activity and tolerability in advanced, elderly NSCLC patients. A total of 56 chemonaive patients were recruited from April 2001 through to March 2002. The dosage schedule, already tested in younger NSCLC patients, was 60 mg/m(2)once a week for three weeks (first cycle), followed by 80 mg/m(2) once a week until disease progression or development of unacceptable toxicity. A limited sampling scheme was used for performing pharmacokinetic analysis on 52 of 56 patients enrolled in the study. Treatment was well tolerated with grade 3/4 neutropenia in 11/17 patients (20/30%) and febrile neutropenia in 1 (2%). Six partial responses (11%) and 25 stable disease responses were recorded, with a disease control rate of 55%. Median overall survival was 8.2 months (95% Confidence Interval (CI) [6.2-11.3]). The clinical benefit response rate was 31% on 32 evaluable patients. Pharmacokinetic profiles appeared quite similar to the historical profiles recorded following i.v. administration. Oral vinorelbine appears to be a reasonable alternative to i.v. vinorelbine, both in terms of activity and tolerability, in advanced, elderly NSCLC patients.
Collapse
Affiliation(s)
- C Gridelli
- Unità Operativa di Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Via Circumvallazione 68, Avellino 83100, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Stahel RA, Weder W, Ballabeni P, Betticher D, Schmid R, Stupp R, Ris HB, Roth A, Mingrone W, Bodis S. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma (MPM): A multicenter phase II trial of the SAKK. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. A. Stahel
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - W. Weder
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - P. Ballabeni
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - D. Betticher
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - R. Schmid
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - R. Stupp
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - H.-B. Ris
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - A. Roth
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - W. Mingrone
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| | - S. Bodis
- Swiss Group for Clinical Cancer Research (SAKK), and Swiss Institute for Applied Cancer Research, Switzerland
| |
Collapse
|
28
|
Gatzemeier U, De Marinis F, Manegold C, Mali P, Portalone L, Castelnau O, Stahel R, Betticher D, Pons J, Gridelli C. 815 Elderly patients (pts) with unresectable localised or metastatic non-small-cell-lung-cancer (NSCLC): results of a phase II study with oral navelbineâ (nvb) given as a weekly monotherapy and first line treatment. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90840-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
29
|
von Rohr A, Schmitz SFH, Tichelli A, Hess U, Piguet D, Wernli M, Frickhofen N, Konwalinka G, Zulian G, Ghielmini M, Rufener B, Racine C, Fey MF, Cerny T, Betticher D, Tobler A. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002; 13:1641-9. [PMID: 12377655 DOI: 10.1093/annonc/mdf272] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND To assess the activity and toxicity of 2-chlorodeoxyadenosine (cladribine, CDA) given by subcutaneous bolus injections to patients with hairy cell leukemia (HCL). PATIENTS AND METHODS Sixty-two eligible patients with classic or prolymphocytic HCL (33 non-pretreated patients, 15 patients with relapse after previous treatment, and 14 patients with progressive disease during a treatment other than CDA) were treated with CDA 0.14 mg/kg/day by subcutaneous bolus injections for five consecutive days. Response status was repeatedly assessed according to the Consensus Resolution criteria. RESULTS Complete and partial remissions were seen in 47 (76%) and 13 (21%) patients, respectively, for a response rate of 97%. All responses were achieved with a single treatment course. Most responses occurred early (i.e. within 10 weeks) after start of CDA therapy, but response quality improved during weeks and even months after treatment completion. The median time to treatment failure for all patients was 38 months. Leukopenia was the main toxicity. Granulocyte nadir (median 0.2 x 10(9)/l) was strongly associated with the incidence of infections (P = 0.0013). Non-specific lymphopenia occurred early after CDA treatment, and normal lymphocytes recovered slowly over several months. No significant associations were found between infections and nadir count of lymphocytes or any lymphocyte subpopulation. No opportunistic infections were observed. CONCLUSIONS One course of CDA given by subcutaneous bolus injections is very effective in HCL. The subcutaneous administration is more convenient for patients and care providers, and has a similar toxicity profile to continuous intravenous infusion. The subcutaneous administration of CDA is a substantial improvement and should be offered to every patient with HCL requiring treatment with CDA.
Collapse
Affiliation(s)
- A von Rohr
- Institute of Medical Oncology, Inselspital, Bern.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- T Cerny
- Department of Internal Medicine, Kantonsspital St. Gallen, Switzerland
| | | |
Collapse
|
31
|
Pichert G, Schmitz SF, Hess U, Cerny T, Cogliatti SB, Betticher D, Stupp R, Schmitter D, Stahel RA, Ghielmini M. Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells. Clin Lymphoma 2001; 1:293-7. [PMID: 11707844 DOI: 10.3816/clm.2001.n.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Rituximab 375 mg/m(2) weekly x 4 has been reported to induce a 60% response rate in patients with relapsed follicular lymphomas (FL). Our aim was to examine the effect of this rituximab schedule on circulating FL cells in an ongoing multicenter study. One hundred fifty-four patients with FL were examined by nested polymerase chain reaction (PCR) at baseline for the presence of t(14;18) translocation-carrying lymphoma cells in bone marrow and/or blood. Sixty-four patients (42%) had PCR-detectable t(14;18)(+) FL cells. Pretreatment characteristics of these 64 patients were as follows: one had stage I, nine had stage II, 14 had stage III, and 40 had stage IV disease. Thirty-five patients had bulky disease (> or = 5 cm) and 25 patients had an elevated serum lactate dehydrogenase (LDH) level. Bone marrow was morphologically assessed in 64 patients, and 39 of these patients had an infiltration with FL cells. Blood samples from 51 patients were available for PCR analysis between weeks 8-12 after induction therapy, and 28 of these patients (55%) were PCR negative. Paired blood and bone marrow samples were available for PCR analysis from 39 patients between weeks 8-12 after induction therapy with rituximab. Thirteen of these patients (33%) did not have PCR-detectable cells in blood and bone marrow, while 26 patients (67%) still had circulating t(14;18)(+) cells in either bone marrow (eight patients), blood (one patient), or both (17 patients). PCR negativity in blood and bone marrow in 13 patients was statistically significantly associated with partial or complete response after induction therapy with rituximab (P = 0.006). However, clearance of PCR-detectable t(14;18)(+) cells in bone marrow and/or blood could not be associated with any low tumor burden pretreatment characteristics such as stages I/II, absence of morphological bone marrow infiltration or tumor bulk of > or = 5 cm, and normal serum LDH.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20/immunology
- Antineoplastic Agents/therapeutic use
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 18/genetics
- Cytogenetic Analysis
- Drug Administration Schedule
- Female
- Humans
- L-Lactate Dehydrogenase/metabolism
- Lymphoma, B-Cell/blood
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/enzymology
- Lymphoma, B-Cell/genetics
- Lymphoma, Follicular/blood
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/enzymology
- Lymphoma, Follicular/genetics
- Male
- Middle Aged
- Neoplasm Staging
- Neoplastic Cells, Circulating/drug effects
- Polymerase Chain Reaction
- Rituximab
- Translocation, Genetic
- Treatment Outcome
Collapse
Affiliation(s)
- G Pichert
- Division of Oncology, The Swiss Group for Clinical Cancer Research, University Hospital, Ramistrasse, Zurich, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Lardinois D, Rechsteiner R, Läng RH, Gugger M, Betticher D, von Briel C, Krueger T, Ris HB. Prognostic relevance of Masaoka and Müller-Hermelink classification in patients with thymic tumors. Ann Thorac Surg 2000; 69:1550-5. [PMID: 10881840 DOI: 10.1016/s0003-4975(00)01140-1] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND To compare the prognostic relevance of Masaoka and Müller-Hermelink classifications. METHODS We treated 71 patients with thymic tumors at our institution between 1980 and 1997. Complete follow-up was achieved in 69 patients (97%) with a mean follow up-time of 8.3 years (range, 9 months to 17 years). RESULTS Masaoka stage I was found in 31 patients (44.9%), stage II in 17 (24.6%), stage III in 19 (27.6%), and stage IV in 2 (2.9%). The 10-year overall survival rate was 83.5% for stage I, 100% for stage IIa, 58% for stage IIb, 44% for stage III, and 0% for stage IV. The disease-free survival rates were 100%, 70%, 40%, 38%, and 0%, respectively. Histologic classification according to Müller-Hermelink found medullary tumors in 7 patients (10.1%), mixed in 18 (26.1%), organoid in 14 (20.3%), cortical in 11 (15.9%), well-differentiated thymic carcinoma in 14 (20.3%), and endocrine carcinoma in 5 (7.3%), with 10-year overall survival rates of 100%, 75%, 92%, 87.5%, 30%, and 0%, respectively, and 10-year disease-free survival rates of 100%, 100%, 77%, 75%, 37%, and 0%, respectively. Medullary, mixed, and well-differentiated organoid tumors were correlated with stage I and II, and well-differentiated thymic carcinoma and endocrine carcinoma with stage III and IV (p < 0.001). Multivariate analysis showed age, gender, myasthenia gravis, and postoperative adjuvant therapy not to be significant predictors of overall and disease-free survival after complete resection, whereas the Müller-Hermelink and Masaoka classifications were independent significant predictors for overall (p < 0.05) and disease-free survival (p < 0.004; p < 0.0001). CONCLUSIONS The consideration of staging and histology in thymic tumors has the potential to improve recurrence prediction and patient selection for combined treatment modalities.
Collapse
Affiliation(s)
- D Lardinois
- Department of Thoracic and Cardiovascular Surgery, Institute of Pathology, University of Berne, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Geisler S, Smith-Sørensen B, Betticher D, Bukholm IK, Akslen LA, Kappeler A, Gugger M, Lønning PE, Børresen-Dale AL. p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy. Breast Cancer Res 2000. [PMCID: PMC3300864 DOI: 10.1186/bcr166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
34
|
Rosell R, Gatzemeier U, Betticher D, Keppler U, Macha H, Pirker R, Berthet P, Breau J, Cortes-Funes H, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. Randomized phase III trial of Taxol®/Carboplatin versus Taxol®Cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer 1999. [DOI: 10.1016/s0169-5002(99)90748-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
von Briel C, Betticher D, Ris H, Greiner R. 2204 III A/B non small cell lung cancer: Quickly alternating, radical radio-/chemotherapy with few side effects. Int J Radiat Oncol Biol Phys 1999. [DOI: 10.1016/s0360-3016(99)90473-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
36
|
Furrer M, Lardinois D, Thormann W, Altermatt HJ, Betticher D, Triller J, Mettler D, Althaus U, Burt ME, Ris HB. Cytostatic lung perfusion by use of an endovascular blood flow occlusion technique. Ann Thorac Surg 1998; 65:1523-8. [PMID: 9647052 DOI: 10.1016/s0003-4975(98)00235-5] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Different modalities of cytostatic lung perfusion were compared regarding plasma and tissue drug concentrations to assess the efficacy of an endovascular blood flow occlusion technique. METHODS A cytostatic lung perfusion study with doxorubicin hydrochloride was performed on large white pigs (n = 12). Plasma and tissue concentrations of doxorubicin were compared for isolated lung perfusion with open cannulation (ILP), blood flow occlusion perfusion with open cannulation of the pulmonary artery alone (BFO), and intravenous drug administration (i.v.). In a fourth group, thoracotomy-free BFO perfusion was performed by endovascular balloon catheterization of the pulmonary artery (endovascular BFO). The 3 animals in this group were used to compare the doxorubicin-perfused pulmonary tissue with the contralateral nonperfused lobes after 1 month. RESULTS The mean lung tissue doxorubicin concentration at the end of perfusion was 19.8 +/- 1.6 microg/g after ILP, 27.6 +/- 2.2 microg/g after BFO (p = not significant), and 3.0 +/- 0.8 microg/g after i.v. perfusion (p < 0.01). Whereas doxorubicin was not detectable in the plasma in the ILP group, concentrations ranged from not detectable to 0.44 microg/mL in the BFO group and from 0.31 to 0.84 microg/mL in the i.v. group (p < 0.05). Mean myocardial tissue concentration was not significantly different after BFO than i.v. perfusion (1.1 +/- 0.5 microg/g and 1.8 +/- 0.1 microg/g, respectively). In the endovascular BFO group, balloon-blocked pulmonary artery perfusion was successfully performed in all animals, and after 1 month, lung tissue showed no cytostatic-induced histologic changes. CONCLUSIONS Compared with ILP, BFO cytostatic lung perfusion produced an insignificantly higher lung-tissue concentration, corresponding to a sixfold to ninefold higher level than after i.v. perfusion. Plasma drug levels during BFO perfusion were lower than during i.v. perfusion. Endovascular BFO may be a promising technique for repeated cytostatic lung perfusion.
Collapse
Affiliation(s)
- M Furrer
- Department of Thoracic and Cardiovascular Surgery, University of Berne, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Furrer M, Lardinois D, Thormann W, Altermatt HJ, Betticher D, Cerny T, Fikrle A, Mettler D, Althaus U, Burt ME, Ris HB. Isolated lung perfusion: single-pass system versus recirculating blood perfusion in pigs. Ann Thorac Surg 1998; 65:1420-5. [PMID: 9594878 DOI: 10.1016/s0003-4975(98)00044-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Cytostatic isolated lung perfusion has been advocated for treating pulmonary metastasis of soft tissue sarcoma. Different techniques of isolated lung perfusion have been developed. METHODS Isolated lung perfusion with and without doxorubicin was performed on white pigs during 15 minutes either by a single-pass system (n = 7) or by a recirculating-blood perfusion system (n = 7). Three animals with endovenous drug application served as controls. Leakage was assessed using isotopic tracers. Perfusion-induced lung tissue injury was determined by postperfusion chest radiographs, by angiotensin-converting enzyme-to-protein ratio in the plasma and in the bronchioalveolar lavage fluid, and by wet-to-dry weight ratio and histologic examination of lung biopsy specimens at 20 and 50 minutes. Doxorubicin concentration in lung tissue and plasma was compared between the three study groups. RESULTS All isolated lung perfusion studies were successfully performed without significant systemic leakage (< 0.6%). Wet-to-dry weight ratio was significantly lower after single-pass as compared with recirculating-blood perfusion and endovenous drug application at both time points (5.0 +/- 1.1 and 5.3 +/- 0.8 for single-pass versus 6.6 +/- 1.1 and 6.9 +/- 0.5 for recirculating-blood versus 6.6 +/- 0.2 and 5.9 +/- 0.7 for the control group, respectively; p < 0.05). Angiotensin-converting enzyme-to-protein plasma ratio in the single-pass group was significantly lower only at 20 minutes (6.3 +/- 2.4 versus 9.3 +/- 1.0 versus 9.7 +/- 1.9, respectively; p < 0.05) but not at 50 minutes. Angiotensin-converting enzyme-to-protein ratio in bronchoalveolar lavage fluid, histology of lung biopsy specimens, and chest radiographs did not differ significantly between the three groups. Doxorubicin lung tissue concentration was not significantly different after single-pass (17.5 micrograms/g) and recirculating-blood perfusion (21.9 micrograms/g), but was significantly higher than after endovenous drug application (3.0 micrograms/g; p < 0.01). CONCLUSIONS Both isolated lung perfusion techniques resulted in a sixfold to sevenfold higher doxorubicin lung tissue concentration than after endovenous application. Isolated lung perfusion-induced lung injury was similar for both techniques, but recirculating-blood perfusion appeared to result in more acute lung injury and was technically more demanding than single-pass perfusion.
Collapse
Affiliation(s)
- M Furrer
- Department of Thoracic and Cardiovascular Surgery, University of Berne, Switzerland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Dallafior S, Pugin P, Cerny T, Betticher D, Saurat JH, Hauser C. [Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide]. Hautarzt 1995; 46:553-60. [PMID: 7558825 DOI: 10.1007/s001050050298] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
We describe the case of a 65-year-old female patient with cutaneous Langerhans' cell granulomatosis without any signs of disease in other organs. She also had systemic lupus erythematosus that had been diagnosed several years before. The coexistence of these two diseases has not been described before as far as we know. The purine analogue 2-chlorodeoxyadenosine (Cladribin), which has been used successfully in the treatment of hairy cell leukaemia, induced complete remission in our patient after 1 week of treatment. After 2 months, however, the patient had a relapse; this was successfully treated with thalidomide. A new understanding of Langerhans' cells granulomatosis as a reactive but not cancerous disease has emerged as a result of recent investigations showing that tumour necrosis factor-alpha (TNF-alpha) plays an important part in the induction of Langerhans' cells from their immature precursors. Because thalidomide has been shown to inhibit TNF-alpha production, down-modulation of this cytokine seems to be a useful treatment strategy in Langerhans' cell granulomatosis. Some asspects of the diagnosis and therapy of this disease are briefly reviewed.
Collapse
Affiliation(s)
- S Dallafior
- Clinique de Dermatologie, Hopital Cantonal Universitaire, Genf, Schweiz
| | | | | | | | | | | |
Collapse
|
39
|
Lorigan P, Lee SM, Betticher D, Woodhead M, Weir D, Hanley S, Hardy C, Thatcher N. Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer. Semin Oncol 1995; 22:32-41. [PMID: 7610397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Although chemotherapy is considered the cornerstone of treatment for small cell lung cancer (SCLC), the majority of SCLC patients relapse and die of their disease within 2 years of diagnosis. Until newer, more effective drugs are developed, both optimization of available chemotherapeutic regimens and the use of combined chemotherapy/radiotherapy will be required to improve the survival of SCLC patients. Combining ifosfamide, carboplatin, and etoposide, among the most active single agents against SCLC, into the ICE regimen was a logical move that has resulted in improved response and survival rates. In limited and extensive SCLC, respectively, ICE and ICE administered with vincristine (VICE) have achieved overall response rates of 79% to 94% and 77% to 100% and 2-year survival rates of 24% to 33% and 9% to 25%, respectively. Treatment-related toxicities, especially myelosuppression, have hindered efforts to accelerate the administration of ICE and VICE regimens and to incorporate them into combined-modality treatments. However, the use of hematologic support measures, including growth factors and peripheral blood progenitor cells, may pave the way for maximizing the effectiveness of these regimens.
Collapse
Affiliation(s)
- P Lorigan
- YCRC Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK
| | | | | | | | | | | | | | | |
Collapse
|